Skip to content

The efficacy of Penetrating Canaloplasty vers Compound Trabeculectomy in Primary Angle-closure Glaucoma(PACG): A Randomized Controlled Trail

The efficacy of Penetrating Canaloplasty vers Compound Trabeculectomy in Primary Angle-closure Glaucoma(PACG): A Randomized Controlled Trail

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IIR-16009009
Enrollment
Unknown
Registered
2016-08-10
Start date
2016-08-12
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Interventions

Penetrating Canaloplasty group (combine canaloplasty with trabeculectomy):Penetrating Canaloplasty (combine canaloplasty with trabeculectomy)
Trabeculectomy group:compound trabeculectomy

Sponsors

Ophthalmology and Optometry Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) All patients were 18-80 years at the time of enrollment, able to understand and provide informed consent, and scheduled for glaucoma surgery; (2) A glaucoma diagnosis of primary angle-closure glaucoma (PACG) which was defined as primary angle closure with glaucomatous optic neuropathy; (3) With glaucomatous optic nerve damage and corresponding visual field defects; (4) With the maximum or tolerable medicament, elevated intraocular pressure may still cause further damage to the optic nerve, or poor compliance; (5) No other histories of fundus disease and eye surgery.

Exclusion criteria

Exclusion criteria: (1) Juvenile glaucoma, traumatic glaucoma, neovascular glaucoma, normal tension glaucoma, secondary glaucoma; (2) Severe heart, lung disease, and advanced cancer; (3) With a history of mental illness; (4) Patients receiving anticoagulant therapy, kidney dialysis and pregnant women; (5) Refused to sign the informed consent; (6) Those who cannot adhere to the follow-up.

Design outcomes

Primary

MeasureTime frame
intraocular pressure;filtering bleb;dry eye syndrom postoperative;

Secondary

MeasureTime frame
anti-glaucoma medicine;

Countries

China

Contacts

Public ContactYuanbo Liang

Ophthalmology and Optometry Hospital,Wenzhou Medical University,Wenzhou,Zhejiang,China

yuanboliang@126.com+86 18257748686

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026